
TFF Pharmaceuticals: Innovating lung disease treatments through advanced dry powder drug delivery.
TFF Pharmaceuticals, founded with a mission to revolutionize drug delivery for lung diseases, leverages its proprietary Thin Film Freezing (TFF) technology to convert medicines into dry powders. This innovative approach enhances the efficacy, safety, and stability of drugs, specifically targeting respiratory conditions. The company focuses on developing and commercializing these advanced formulations to provide faster and more effective treatments for lung-related ailments.
Notable figures associated with TFF Pharmaceuticals include experts in biopharmaceuticals and respiratory medicine. The company has attracted significant investment from industry leaders, fostering rapid development and commercialization of its products. Key achievements include the successful creation of numerous dry powder formulations that have demonstrated improved delivery and outcomes in preclinical studies. TFF Pharmaceuticals continues to impact the biopharmaceutical landscape by offering groundbreaking solutions for lung disease treatment.

Respira Therapeutics

Transpire Bio
transpirebio.com

TBT Pharma
tbtpharma.com

Theron Pharmaceuticals

Qnovia
qnovia.com

Avalyn Pharma
avalynpharma.com

Nob Hill Therapeutics

Terns Pharmaceuticals
ternspharma.com

Therabron Therapeutics
therabron.com

Tigris Pharmaceuticals
tigrispharma.com

Transport Pharmaceuticals

NovaDel Pharma

Pulmatrix
pulmatrix.com

Novel Therapeutic Technologies
ntt-inc.com

Vitranu
vitranu.com
Companies similar to TFF Pharmaceuticals include Respira Therapeutics, Transpire Bio, TBT Pharma and Theron Pharmaceuticals.
TFF Pharmaceuticals was founded in 2018.
TFF Pharmaceuticals' headquarters is located in Austin, TX, US.
TFF Pharmaceuticals' most recent funding round was for $5M (USD) in August 2023.
As of Aug 15, 2023, TFF Pharmaceuticals has raised a total of $66.9M (USD).
TFF Pharmaceuticals has 15 employees as of Feb 6, 2024.